Pilot studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure.

Abstract

After an initial safety study in 7 normal volunteers, a randomized double-blind comparison was made between 3,5-diiodothyropropionic acid (DITPA) and placebo in 19 patients with moderately severe congestive failure. In heart failure patients receiving the drug for 4 weeks, cardiac index was increased (p = 0.04) and systemic vascular resistance index was decreased (p = 0.02). Systolic cardiac function was unchanged but isovolumetric relaxation time was decreased significantly, suggesting improvement in diastolic function. Total serum cholesterol (p = 0.005) and triglycerides (p = 0.01) also were decreased significantly. DITPA could represent a useful new agent for treatment of congestive heart failure.

• Authors: Eugene Morkin, Gregory Pennock, Peter H Spooner, Joseph J Bahl, Katherine Underhill Fox, Steven Goldman
• Journal: Cardiology (Cardiology) Vol. 97 Issue 4 Pg. 218-25 ( 2002) ISSN: 0008-6312 [Print] Switzerland
• PMID: 12145478 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, Non-P.H.S.)
• Copyright: Copyright 2002 S. Karger AG, Basel

Chemical References

• Cholesterol, HDL
• Cholesterol, LDL
• Diiodothyronines
• Propionates
• Thyroid Hormones
• 3,5-diiodothyropropionic acid
• Thyrotropin

Topics

• Adult
• Cholesterol, HDL (blood, drug effects)
• Cholesterol, LDL (blood, drug effects)
• Diiodothyronines (therapeutic use)
• Dose-Response Relationship, Drug
• Double-Blind Method
• Heart Failure (blood, drug therapy)
• Hemodynamics (drug effects)
• Humans
• Male
• Middle Aged
• Pilot Projects
• Propionates (therapeutic use)
• Thyroid Hormones (blood, therapeutic use)
• Thyrotropin (blood, drug effects)
• Time Factors
• Treatment Outcome
• Ventricular Function, Left (drug effects)